Clinical Trials Search
A Phase Ib, Multicenter Study To Determine The Safety And Tolerability of Tisagenlecleucel in Combination with Ibrutinib in Adult Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma
A multi-center, open-label, phase Ib study to evaluate the safety and tolerability of the administration of tisagenlecleucel in combination with ibrutinib in patients with r/r DLBCL who have received two or more lines of systemic therapy, including an anti-CD20 and anthracycline based chemotherapy, and who have progressed after or are not candidates for ASCT.
The primary objective of this study is to assess the safety and tolerability of tisagenlecleucel in combination with ibrutinib
748645 (Ibrutinib); Ibrutinib (Imbruvica); PCI-32765 (Ibrutinib); Tisagenlecleucel ()